NCT06593314
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
At risk: Primary completion moved 8 months later.
See at-risk trials from University of Texas Southwestern Medical Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 15, 2026 to May 15, 2027
- Eligibility criteria expanded, about 4 words
- Study completion pushed from Oct 15, 2026 to Jul 15, 2027
- Study description revised
- Notable Primary completion date: Mar 15, 2026 to Sep 15, 2026
- Study completion date: Jun 15, 2027 to Oct 15, 2026
Notable Trial status: Not Yet Recruiting to Recruitingv5 Show 9 more changesShow less
- Enrollment target: 50 to 800
- Eligibility criteria revised
- Primary endpoints revised (2)
- Primary completion date: Dec 15, 2025 to Mar 15, 2026
- Start date changed from estimate of Jul 15, 2025 to Aug 6, 2025
- Interventions: Clinical Decision Support (Behavioral) to Message with EchoGo (Behavioral), Standard Message (Behavioral)
- Secondary endpoints revised (3)
- Study description expanded, about 123 words
- Site details revised
- Notable Start date: Apr 15, 2025 to Jul 15, 2025v4
- Notable Start date: Jan 15, 2025 to Apr 15, 2025v3
- Notable Start date: Oct 15, 2024 to Jan 15, 2025
- Study description expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Provider will receive a computer-based alert notifying them that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standard-of-care recommendations for the use of SGLT-2 inhibitors and/or GLP-1 RA (if obesity is present). The purpose of the alert is to inform the providers about the risk of heart failure and provide them guidance regarding the guideline-recommended standard of care. The providers can choose to provide care as deemed fit based on the information provided
We will provide a standard message to the provider detailing guideline-recommended medications for type 2 diabetes. This will not contain information about the Ultromics EchoGo algorithm. The providers can choose to provide care as deemed fit based on the information provided
Behavioral: Message with EchoGo, Standard Message
Sites
1 site in 1 country
- UT Southwestern Medical CenterDallas, Texas, United States